Chapter 42:The Briefing

She had walked these corridors as Isabella Thorne — the heir, the future, the golden child. She had attended board meetings with Richard, observed her grandfather's final years of active management, and learned the geography of corporate power by osmosis. The elevator bank that served the 40th floor was separate from the rest — a private lift that required an executive-level keycard and a biometric scan. Catherine Marsh's level-two badge would not open it. But today, David Choi had brought her up as part of the briefing team. His executive badge had bypassed the security protocols, and Leah had followed him through the turnstile without being scanned. A procedural oversight, or a deliberate choice — she didn't know and didn't care. She was on the 40th floor, and she was about to be in the same room as the people who had tried to kill her. The executive floor was different from the 34th. Where the 34th was open-plan and egalitarian, the 40th was a maze of private offices with frosted glass doors, mahogany-paneled conference rooms, and original artwork on the walls — Rothkos, de Koonings, a Basquiat that Leah remembered from childhood. The carpet was thicker. The lighting was softer. The air smelled of leather and old money. David walked briskly, briefing folder under his arm. Leah followed two steps behind, her own folder clutched against her chest. She had spent four days preparing the clinical diagnostics and pharmaceutical segment — forty pages of analysis, charts, and projections. The work was excellent, because it was real. Catherine Marsh was a competent analyst, and Isabella Thorne had been trained by the best. "Conference room 40-A," David said, stopping at a door at the end of the corridor. "The attendees include Martha Thorne, Richard Thorne, Antonio Costa, and two Foundation trustees. I'll present the overview. You'll present the clinical diagnostics section — pages twelve through twenty-four. Stay on script. Don't elaborate unless asked. Don't make eye contact with Martha for more than two seconds." Leah's pulse quickened. She kept her voice level. "Understood." David opened the door. The conference room was large — a rectangular table seating twelve, with floor-to-ceiling windows overlooking Park Avenue. Four people were already seated: a woman at the far end of the table, two men to her left, and a third man to her right. The woman was Martha Thorne. Leah saw her with Isabella's eyes first — the silver hair, the impeccable posture, the thin hands folded on the table. Martha was eighty-three years old, but she occupied the room with the gravitational authority of someone who had been commanding spaces like this for six decades. She wore a cream-colored suit with a single strand of pearls. Her face was composed, her expression unreadable. The two men to her left were Antonio Costa — Sebastian's father, a heavyset man in his sixties with a permanent expression of mild irritation — and a thin, gray-haired man Leah didn't recognize. The man to Martha's right was Richard Thorne. Richard. Leah's breath caught. She controlled it immediately — a microsecond of hesitation, invisible to anyone who wasn't looking for it. But Richard might have been looking. He had always been the one who saw her, even when she was trying to hide. He looked older. Thinner. The grief had carved lines into his face that hadn't been there two years ago. His hair was more gray than brown, and his eyes — the same warm brown eyes that Leah remembered from a thousand childhood moments — were shadowed and tired. He wore a dark suit, but it hung loosely on him, as if he had lost weight and hadn't bothered to replace his wardrobe. He was staring at the table. He hadn't noticed her yet. Leah took her seat next to David, at the near end of the table. She placed her folder in front of her and opened it to page twelve. Her hands were steady. Her face was neutral. Catherine Marsh was a junior analyst presenting data to senior executives. Nothing more. David began the presentation. His voice was confident and professional, walking the attendees through the overview of Costa Holdings' healthcare portfolio. Market size, competitive positioning, growth projections. Standard corporate fare. Leah half-listened while she scanned the room. Martha Thorne was watching David with an expression of polite attention. She was not taking notes. She was not looking at the slides. She was listening, but her focus was elsewhere — on the room, on the people, on the power dynamics that flowed beneath the surface of every corporate interaction. Antonio Costa was visibly tense. The NYT article and the SEC inquiry had been out for five days, and the pressure was showing. He kept touching his tie, adjusting his cuffs, shifting in his chair. He was a man who was not accustomed to being scrutinized, and he was finding the experience unbearable. The third man — the one Leah didn't recognize — was taking notes on a tablet. Mid-fifties, silver hair, expensive watch. A Foundation trustee, probably. His expression was professionally neutral. Richard was still staring at the table. David finished the overview and transitioned to the clinical diagnostics segment. "Catherine Marsh will walk you through the diagnostics and pharmaceutical analysis." Leah stood. She moved to the screen at the end of the room and clicked to her first slide. She began speaking — clearly, concisely, without notes. She had memorized the data. She didn't need the folder. "The clinical diagnostics segment represents approximately 12% of Costa Holdings' healthcare portfolio by revenue. The segment has grown at a compound annual rate of 8.3% over the past five years, driven primarily by acquisitions in the point-of-care testing market." She moved through the slides. Market data. Competitive analysis. Growth projections. The attendees followed along, some more closely than others. Antonio Costa was watching the screen with the intensity of a man looking for a lifeline. The trustee was still taking notes. Martha was watching Leah. Not the slides. Leah. It lasted three seconds. Maybe four. Martha's gaze shifted from the screen to Leah's face, lingered, and then moved back to the screen. There was no recognition in her eyes — how could there be? Catherine Marsh was a different person with different hair, different posture, different voice. But Martha was looking, and Martha was assessing, and Martha had the particular instinct of a predator who could sense when something in her territory was not what it appeared to be. Leah held her gaze for exactly two seconds — David's instruction — and then looked away. She continued presenting. The pharmaceutical section was next. Revenue data, pipeline analysis, regulatory landscape. Leah moved through it efficiently, highlighting the key findings and flagging the areas of risk. One of those areas was NexGen Therapeutics. "NexGen represents the largest single acquisition in the portfolio, at $340 million," Leah said. "The clinical trial data has shown promising results in Phase III, with a projected FDA approval timeline of Q4 2024. However, there is a noted variance between reported trial outcomes and raw patient records — approximately 3.7% — which has been attributed to data entry inconsistencies in the trial management system." She said it carefully. The 3.7% variance was real — Sofia's report had documented it, and the FDA inspection had confirmed it. But Leah's framing was deliberately benign: "data entry inconsistencies," not "falsified clinical data." She was presenting the information as a minor procedural issue, not a material risk. Antonio Costa shifted in his chair. Martha's expression didn't change. "Can you elaborate on the variance?" Martha asked. Her voice was soft, precise, and carried the weight of someone who expected complete answers. "Certainly." Leah clicked to a supplementary slide. "The 3.7% variance is within the range observed in similar Phase III trials for pharmaceutical products in this therapeutic category. Industry benchmarks show variance rates of 15 to 25 percent for raw-versus-reported data, primarily due to transcription errors, missing entries, and protocol deviations. The NexGen variance is significantly below the industry average, suggesting strong data management practices overall." This was true, but misleading. The variance was below average because the raw data had been adjusted — not because the data management was strong. Leah knew this. Sofia's report had documented the adjustment methodology. But Catherine Marsh was presenting the data as it appeared in ThorneVault, and ThorneVault's version was sanitized. Martha nodded. "Thank you. Continue." Leah continued. She finished the pharmaceutical section and handed the presentation back to David, who closed with a summary and next steps. The attendees asked a few questions — Antonio wanted to know about the ROI projections for the medical device segment; the trustee asked about regulatory risk exposure across the portfolio. Leah answered the questions that were directed at her with concise precision. The meeting lasted forty-five minutes. David thanked the attendees and gathered his materials. Leah followed him to the door. She was three steps from the exit when Richard Thorne spoke. "David. A moment." David stopped. Leah stopped. She didn't turn around. "Of course, Richard." "I wanted to compliment your team. The analysis is thorough. Especially the pharmaceutical section — the clinical data variance analysis was well-framed." Leah's back was to Richard. She could feel his gaze on her. She could feel the weight of every childhood moment — every boardroom she had sat in beside him, every lesson he had taught her about reading a balance sheet, every evening they had spent together in his study while the rest of the house slept. She wanted to turn around. She wanted to see his face. She wanted to say his name. She didn't. "Thank you, Richard," David said. "Catherine Marsh prepared the pharmaceutical section. She's one of our new analysts — joined us from a consulting background." "Catherine Marsh." Richard repeated the name. Leah could hear something in his voice — not recognition, not suspicion, but a faint resonance, as if the name had triggered a distant association that he couldn't quite place. "A pleasure to meet you, Mr. Thorne," Leah said, turning her head just enough to acknowledge him without making eye contact. She kept her voice level, her posture neutral, her expression professional. Richard looked at her. For one second — one terrible, infinite second — his eyes met hers. Something flickered across his face. Not recognition. Something deeper. Something older. The look of a father who had lost his daughter and saw, in a stranger's face, a ghost of something familiar. Then it was gone. "Pleasure to meet you, Ms. Marsh," Richard said. His voice was steady, but Leah could hear the fracture beneath it — the controlled grief of a man who had been broken and was holding himself together with willpower alone. Leah nodded, turned, and walked out of the conference room. She did not look back. --- 3:15 PM. Elevator bank C, descending. David was on his phone, reviewing something. Leah stood beside him, staring at the elevator doors, her hands at her sides. Her palms were sweating. Her heart was pounding. She controlled both. "Good job in there," David said without looking up. "Martha doesn't compliment often, and she listened to your section more carefully than the rest. That's a good sign." "Thank you." "Richard's comment was unusual too. He doesn't usually engage with junior analysts. Something about your presentation caught his attention." Leah said nothing. "Keep it up. I'll have more work for you next week — the SEC inquiry is going to generate a lot of internal analysis requests, and I want you on the response team." The SEC inquiry response team. More access. More information. More exposure. "I'd be happy to help," Leah said. The elevator doors opened on the 34th floor. Leah walked to her cubicle, sat down, and opened the Moleskine — hidden inside her bag, beneath the Thorne Group notebook. *April 7. Day fourteen.* *I was in the same room as Martha Thorne. She looked at me for three seconds. No recognition. But she was assessing — she always assesses.* *I was in the same room as Richard Thorne. He said my name. Catherine Marsh. He looked at me, and something moved behind his eyes. Not recognition — something else. Something I can't name.* *He's thinner. He's diminished. He stands behind Martha and takes notes while she runs the room. This is not the man who taught me to read a balance sheet. This is a man who has been emptied.* *Martha did that to him. Martha did that to everyone.* *I presented the NexGen data to the people who created the fraud. I framed the 3.7% variance as a minor procedural issue. I used Sofia's data against itself — taking the truth and reshaping it to protect the lie. Catherine Marsh's analysis was technically accurate and strategically misleading. It was exactly what David wanted.* *It was the hardest thing I've ever done.* *The executive briefing is over. The SEC inquiry response team is forming. Catherine Marsh is being pulled deeper into the company's inner workings.* *But I am closer now. Closer to Martha. Closer to the truth. Closer to whatever is hidden on the 36th floor and in Martha's private archive.* *The Voss question is still the key. And Richard's eyes — that flicker of something unnameable — is another piece of the puzzle.* *Day fourteen. The infiltration is holding. But the cost is mounting.* *Isabella is not okay.* *Catherine Marsh has to be.* --- Leah closed the Moleskine and put it back in her bag. She opened ThorneVault and began working on the next analysis request — a market comparison for Costa Holdings' surgical robotics portfolio. The work was real, the data was clean, and the task required enough concentration to keep her mind from replaying Richard's face. She worked for three hours without stopping. At 6:30, she closed her laptop, packed her bag, and left the building. Outside, the evening was cold and bright. The sidewalks were crowded with the end-of-day exodus. Leah walked south on Park Avenue, then west on 51st, then north on Lexington toward her apartment. She was halfway home when her phone buzzed. A text from Ethan: *Background check on Rachel Okonkwo is clean. No known ties to Thorne family. She's been at the company 6 years, recruited from Goldman Sachs. Performance reviews are excellent. One notation: she filed an internal ethics complaint in 2021 regarding the Veritas Labs acquisition. Complaint was reviewed and dismissed by HR.* Leah stopped walking. An ethics complaint. In 2021. About Veritas Labs — the same truncated due diligence, the same HT directive, the same Foundation financing that Leah had discovered on her second day. Rachel had noticed the problem three years ago. She had filed a formal complaint. And HR — presumably acting on Martha's instructions — had dismissed it. Rachel was not a sentinel. Rachel was a canary in the coal mine — someone who had seen the rot and tried to report it, only to be silenced. Leah typed a response: *She's an ally. How do you want to approach?* Ethan's reply came thirty seconds later: *Not yet. Let the SEC inquiry play out. When the pressure is highest, she'll be most receptive. Timing matters.* Leah put her phone away and resumed walking. The pieces were aligning. The NYT article had cracked the facade. The SEC inquiry was expanding. Hunt Capital was verifying the PRI pattern. Rachel Okonkwo was a potential ally with a grudge. And Catherine Marsh was inside, gathering intelligence, building trust, and waiting for the moment to strike. But the Voss question was still unanswered. The physical archive was still inaccessible. And Richard Thorne had looked at her with eyes that held something she couldn't name. Day fourteen. The infiltration was holding. The cost was mounting. And somewhere in the gap between Catherine Marsh and Isabella Thorne, Leah was beginning to wonder how much of herself she could lose before there was nothing left to find.